false000146874800014687482023-08-162023-08-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 16, 2023

 

 

Kodiak Sciences Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38682

27-0476525

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1200 Page Mill Rd

 

Palo Alto, California

 

94304

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 650 281-0850

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001

 

KOD

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 16, 2023, Jason Ehrlich, M.D., Ph.D., informed the Company of his resignation as Chief Medical Officer and Chief Development Officer of the Company, effective August 25, 2023. Dr. Ehrlich’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KODIAK SCIENCES INC.

 

 

 

 

Date:

August 17, 2023

By:

/s/ Victor Perlroth

 

 

 

Victor Perlroth, M.D.
Chief Executive Officer

 

v3.23.2
Document And Entity Information
Aug. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 16, 2023
Entity Registrant Name Kodiak Sciences Inc.
Entity Central Index Key 0001468748
Entity Emerging Growth Company false
Securities Act File Number 001-38682
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-0476525
Entity Address, Address Line One 1200 Page Mill Rd
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94304
City Area Code 650
Local Phone Number 281-0850
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol KOD
Security Exchange Name NASDAQ
Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Kodiak Sciences Charts.
Kodiak Sciences (NASDAQ:KOD)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Kodiak Sciences Charts.